COGENT BIOSCIENCES INC (COGT:NASDAQ)

$32.74 -0.67 (-2.0054%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 79

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed COGENT BIOSCIENCES INC (COGT:NASDAQ) News Sources

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

23-05-2026

fool.com

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

28-05-2026

yahoo.com

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

30-05-2026

yahoo.com

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

10-06-2026

yahoo.com

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

12-06-2026

yahoo.com

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

12-06-2026

yahoo.com

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

12-06-2026

yahoo.com

Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?

22-06-2026

yahoo.com

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

30-06-2026

yahoo.com

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

15-09-2026

yahoo.com

COGENT BIOSCIENCES INC (COGT:NASDAQ) Sentiment Trend

0 25 50 75 100 91 76 79 85 77 77 88 91 55 70 23-05-2026 28-05-2026 30-05-2026 10-06-2026 12-06-2026 22-06-2026 30-06-2026 15-09-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

COGENT BIOSCIENCES INC (COGT:NASDAQ) FAQs

toggle

What is the current price of COGENT BIOSCIENCES INC (COGT:NASDAQ)?

The current price of COGENT BIOSCIENCES INC (COGT:NASDAQ) is $32.74.


toggle

COGENT BIOSCIENCES INC (COGT:NASDAQ) absolute price change since previous trading day?

The absolute price change of COGENT BIOSCIENCES INC (COGT:NASDAQ) since the previous trading day is $-0.67.


toggle

COGENT BIOSCIENCES INC (COGT:NASDAQ) percentage price change since previous trading day?

The percentage price change of COGENT BIOSCIENCES INC (COGT:NASDAQ) since the previous trading day is -2.0054%.


toggle

What is the most recent average sentiment score for COGENT BIOSCIENCES INC (COGT:NASDAQ)?

The most recent average sentiment score for COGENT BIOSCIENCES INC (COGT:NASDAQ) is 79 out of 100.


toggle

What is the most recent average sentiment for COGENT BIOSCIENCES INC (COGT:NASDAQ)?

The most recent sentiment for COGENT BIOSCIENCES INC (COGT:NASDAQ) is .


SEC-8K** Filing Available For COGENT BIOSCIENCES INC (COGT:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.